8-K: STERIS plc Announces Fiscal 2024 Results and Restructuring Plan

STERIS plc reported a 12% increase in fiscal 2024 revenue to $5.5 billion and announced a targeted restructuring plan expected to yield $25 million in annual EBIT improvement.

Summary

• STERIS plc announced its financial results for the fourth quarter and full fiscal year 2024, ending March 31, 2024.
• Total fiscal year revenue increased by 12% to $5.5 billion, compared to $5.0 billion in fiscal 2023.
• Constant currency organic revenue from continuing operations for the full year increased by 10% to $5.0 billion.
• U.S. GAAP earnings per diluted share for the full year were $3.81, while adjusted earnings per diluted share increased to $8.83.
• The company announced a targeted restructuring plan, which includes restructuring of the Healthcare surgical business in Europe, with anticipated charges of approximately $100 million.
• Approximately $44.4 million of the restructuring charges were recorded in the fiscal 2024 fourth quarter, with the remainder expected in fiscal 2025.
• The restructuring is expected to result in approximately $25 million per year in EBIT improvement, with the majority of the benefit realized in fiscal 2026 and beyond.
• For fiscal 2025, the company expects revenue from continuing operations to increase by 6.5-7.5% and adjusted earnings per diluted share to be in the range of $9.05 to $9.25.
• Free cash flow for fiscal 2024 was $620.3 million, compared to $409.6 million in the prior year, and is expected to be approximately $700 million in fiscal 2025.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The strong revenue growth and positive outlook are encouraging, but the restructuring costs and GAAP losses temper the overall sentiment. The strategic moves are positive for the long term.

Positives

• STERIS achieved strong revenue growth in fiscal 2024, with a 12% increase to $5.5 billion.
• The Healthcare segment showed strong performance, driven by strength in the United States.
• Free cash flow increased significantly in fiscal 2024 to $620.3 million.
• The company anticipates a $25 million annual EBIT improvement from the restructuring plan.
• STERIS expects continued revenue and earnings growth in fiscal 2025.

Negatives

• U.S. GAAP net loss for the fourth quarter was $1.4 million, or ($0.01) per diluted share.
• The fiscal 2024 fourth quarter and full year U.S. GAAP results were negatively impacted by a pre-tax loss of $206.4 million due to the reclassification of the Dental segment to discontinued operations.
• The company will incur approximately $100 million in restructuring charges, with $44.4 million recorded in the fiscal 2024 fourth quarter.
• The restructuring plan includes the impairment of an internally developed X-ray accelerator, product rationalizations and facility consolidations.

Risks

• The successful implementation of the restructuring plan is subject to assumptions, risks, and uncertainties, and actual results may differ from estimates.
• The company may incur additional costs not currently contemplated due to events associated with the restructuring plan.
• The divestiture of the Dental segment is dependent on the satisfaction of certain closing conditions, some of which are outside of STERIS's control.
• Regulatory approvals required to complete the Dental segment divestiture may not be received or may take longer than expected.
• The company faces risks related to market conditions, political events, competitive factors, technology advances, and regulatory actions.
• There are uncertainties related to tax treatments and the potential impact of Pillar Two Model Rules.
• The company is exposed to risks from international unrest, economic downturns, and changes in trade barriers.

Future Outlook

For fiscal 2025, the company expects revenue from continuing operations to increase by 6.5-7.5% and adjusted earnings per diluted share to be in the range of $9.05 to $9.25. Free cash flow is expected to be approximately $700 million.

Management Comments

• We are pleased with the strong finish to the fiscal year, as our Healthcare segment continued their trend of outperformance, driven primarily by strength in the United States, said Dan Carestio, President and CEO of STERIS.
• We have made several strategic decisions in fiscal 2024 that will position STERIS for future growth, including todays targeted restructuring announcement and the announcement to divest the Dental segment.
• Heading into fiscal 2025, I am confident in our ability to deliver on our long-term commitments of mid-to-high single digit revenue growth and double-digit earnings growth.

Industry Context

The announcement reflects a strategic shift for STERIS, focusing on core healthcare and life sciences businesses while divesting the dental segment. This is in line with industry trends where companies are streamlining operations to focus on high-growth areas and improve profitability.

Comparison to Industry Standards

• STERIS's 12% revenue growth for fiscal 2024 is strong compared to some of its peers in the medical device and healthcare services industry, such as Medtronic and Baxter, which have seen more modest growth.
• The restructuring plan, while incurring short-term costs, is aimed at improving long-term profitability, a common strategy among large healthcare companies.
• The divestiture of the Dental segment is similar to moves by other diversified healthcare companies to focus on core competencies.
• The projected free cash flow of $700 million for fiscal 2025 is a positive indicator of financial health and is comparable to other well-established companies in the sector.

Stakeholder Impact

• Shareholders will be impacted by the restructuring charges in the short term but should benefit from improved profitability in the long term.
• Employees may be affected by the restructuring plan, including potential job losses.
• Customers should not be significantly impacted by the restructuring, as the company focuses on core businesses.
• Suppliers may see changes in demand due to product rationalizations and facility consolidations.
• Creditors will be impacted by the company's debt levels and cash flow.

Next Steps

• The company will complete the restructuring plan by the end of fiscal 2025.
• The company will continue to execute its strategy to focus on core healthcare and life sciences businesses.
• The company will complete the divestiture of the Dental segment.
• STERIS management will host a conference call on May 9, 2024, to discuss the financial results.

Key Dates

Keywords

STERIS, financial results, restructuring, healthcare, revenue, earnings, EBIT, divestiture, Dental segment, free cash flow, medical devices, sterilization, life sciences